These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 1902420

  • 21. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
    Maheux R, Lemay A, Turcot-Lemay L.
    Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
    [Abstract] [Full Text] [Related]

  • 22. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R, Gesenhues T, Deichert U, Duda V, Sturm G, Schulz KD.
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
    Rolland R, Franssen AM, Willemsen WN, Corbey RS.
    Prog Clin Biol Res; 1986 Feb; 225():313-20. PubMed ID: 3097670
    [No Abstract] [Full Text] [Related]

  • 25. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A, Maheux R, Faure N, Jean C, Fazekas AT.
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [Abstract] [Full Text] [Related]

  • 26. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH, Shaw RW, Nye M.
    Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
    [Abstract] [Full Text] [Related]

  • 27. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H, Kobori H, Kikuchi I, Sato Y, Mitsuhashi N.
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [Abstract] [Full Text] [Related]

  • 28. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt EH.
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [Abstract] [Full Text] [Related]

  • 29. Calcium metabolism in premenopausal women treated by a Gn-RH agonist for uterine myoma.
    Ito M, Sakoda Y, Okamura H.
    Endocrinol Jpn; 1990 Dec; 37(6):907-13. PubMed ID: 1966283
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
    Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F.
    Fertil Steril; 1989 Jun; 51(6):947-50. PubMed ID: 2498131
    [Abstract] [Full Text] [Related]

  • 32. Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist.
    Friedman AJ, Daly M, Juneau-Norcross M, Rein MS.
    Fertil Steril; 1992 Aug; 58(2):413-5. PubMed ID: 1633911
    [Abstract] [Full Text] [Related]

  • 33. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 34. [Medical treatment of uterine leiomyomatosis with an agonist of pituitary gonadotropins (GnRH). Presentation of a case].
    Bustos HH, López Garcia R, Sánchez V, Contreras J, Ayala Ruiz A.
    Ginecol Obstet Mex; 1990 Sep; 58():260-4. PubMed ID: 2125961
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
    Jaakkola T, Ding YQ, Kellokumpu-Lehtinen P, Valavaara R, Martikainen H, Tapanainen J, Rönnberg L, Huhtaniemi I.
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
    [Abstract] [Full Text] [Related]

  • 39. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I, Venho P, Jacobi G, Rannikko S.
    J Androl; 1991 Jun; 12(1):46-53. PubMed ID: 1901309
    [Abstract] [Full Text] [Related]

  • 40. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women.
    Sherman BM, West JH, Korenman SG.
    J Clin Endocrinol Metab; 1976 Apr; 42(4):629-36. PubMed ID: 1262439
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.